Health Trials

Advanced or Metastatic Non-Small Cell Lung Cancer

5

Review clinical trials related to Advanced or Metastatic Non-Small Cell Lung Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Participants needed: 152
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jun 17, 2026Locations: 103
Eligibility criteria

Participants with confirmed squamous or non-squamous NSCLC with a current Stage... [+9]

Participants with epidermal growth factor receptor mutations, anaplastic lymphom... [+27]

Read more
Status: Recruiting

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer

Participants needed: 248
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.Updated: Dec 23, 2025Locations: 1
Eligibility criteria

Have the ability to give informed consent, have signed informed and able to comp... [+8]

Active or symptomatic brain metastases. [+30]

Read more
Status: Recruiting

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.

Participants needed: 460
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.Updated: Nov 18, 2025Locations: 1
Eligibility criteria

Voluntary participation and written informed consent. [+6]

Have untreated central nervous system metastasis; or have meningeal metastasis o... [+5]

Read more
Status: Recruiting

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Phase I: To evaluate the safety, tolerance and effectiveness of IAP0971 for the treatment of advanced malignant tumors. Phase II: Evaluation of IAP0971 therapy driver negative and PD-L1 positive (TPS≥50%) The initial treatment is effective in subjects with advanced or metastatic non-small cell lung cancer.

Participants needed: 78
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: SUNHO（China）BioPharmaceutical CO., Ltd.Updated: Jan 15, 2025Locations: 1
Eligibility criteria

Age of 18-75 years old (including cut-off value), regardless of gender. [+9]

Phase II only: small cell lung cancer or sarcomatoid lesion confirmed by histopa... [+20]

Read more
Status: Recruiting

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

To evaluate the efficacy, safety, recurrence site, recurrence pattern and resistance mechanism of 160mg furmonertinib as first-line therapy in advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR classical mutations(19Del or L858R).

Participants needed: 144
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Peking Union Medical College HospitalUpdated: Nov 5, 2024Locations: 1
Eligibility criteria

≥ 18 years old, Male or Female [+9]

NSCLC with predominant squamous cell histology, small cell lung cancer or neuroe... [+18]

Read more